Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 19/20 | 0.46 |
| ▸ | FLT1 | P17948 | 12/20 | 0.46 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375976 | 0.89 | KDR (0.54) | METKDRFLT1MST1R | |
| SCHEMBL1251064 | 0.89 | KDR (0.54) | METKDRFLT1MST1R | |
| SCHEMBL5243242 | 0.88 | MET (0.52) | METKDRFLT1MST1R | |
| SCHEMBL5240822 | 0.86 | MET (0.53) | METKDRFLT1MST1R | |
| SCHEMBL5240980 | 0.86 | MET (0.53) | METKDRFLT1MST1R | |
| SCHEMBL14409955 | 0.81 | KDR (0.52) | METKDRFLT1MST1R | |
| SCHEMBL5240142 | 0.80 | MET (0.51) | METKDRFLT1MST1R | |
| SCHEMBL5243429 | 0.77 | KDR (0.71) | METKDRFLT1MST1R | |
| SCHEMBL5243195 | 0.76 | KDR (0.46) | METKDRFLT1 | |
| SCHEMBL14409851 | 0.76 | KDR (0.57) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515975-B1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1515975-B1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7045528-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1515975-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6869962-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MET 2469/4885KDR 1885/4885FLT1 1091/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MET 2469/4885KDR 1885/4885FLT1 1091/4885 |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | TPD52L2, DPYD, CCND2 | MET 2699/4885KDR 1802/4885FLT1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.